Volume 68, Issue 4, Pages (October 2005)

Slides:

Advertisements

Similar presentations

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.

Advertisements

Kamyar Kalantar-Zadeh Kidney International

Steven Fishbane, Jeffrey S. Berns, M.D. Kidney International

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Volume 67, Pages S1-S7 (June 2005)

Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities

Volume 70, Issue 8, Pages (October 2006)

Renal vitamin D receptor expression and vitamin D renoprotection

Anemia management in chronic kidney disease

Stem cells for kidney repair: useful tool for acute renal failure?

Circulating biochemical markers of bone remodeling in uremic patients

Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities

Reassessment of the care of the patient with chronic kidney disease

Progression of renal failure and hypertensive nephrosclerosis

Volume 63, Pages S88-S90 (June 2003)

C-reactive protein and dialysis access

Volume 54, Issue 2, Pages (August 1998)

Volume 68, Issue 4, Pages (October 2005)

Volume 58, Issue 1, Pages (July 2000)

Kamyar Kalantar-Zadeh Kidney International

Volume 76, Pages S50-S99 (August 2009)

Volume 71, Issue 1, Pages (January 2007)

Volume 82, Issue 8, Pages (October 2012)

Comorbidity and confounding in end-stage renal disease

Volume 70, Issue 11, Pages (December 2006)

The need for reliable serum parathyroid hormone measurements

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Nephrology Crosswords: Hemodialysis

Use of vitamin D in chronic kidney disease patients

Florian Lang, Michael Föller Kidney International

Gentamicin pharmacokinetics during slow daily home hemodialysis

Study of Heart and Renal Protection (SHARP)

Volume 54, Issue 3, Pages (September 1998)

Volume 70, Issue 12, Pages (December 2006)

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Volume 79, Issue 2, Pages (January 2011)

Blood pressure targets in hemodialysis patients

Volume 75, Issue 11, Pages (June 2009)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 87, Issue 3, Pages (March 2015)

Alternate-day dialysis may be needed for hemodialysis patients

Volume 68, Issue 3, Pages (September 2005)

Counteracting progression of renal disease: A look into the future

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

Circadian regulation of renal function

Renal Osteodystrophy: α-Heremans Schmid Glycoprotein/Fetuin-A, Matrix GLA Protein Serum Levels, and Bone Histomorphometry Giorgio Coen, MD, Paola Ballanti,

Volume 73, Issue 6, Pages (March 2008)

Volume 56, Issue 4, Pages (October 1999)

Volume 54, Issue 1, Pages (July 1998)

Current status of maintenance hemodialysis in Beijing, China

Volume 60, Issue 3, Pages (September 2001)

Organ transplantation goes to the movies

Volume 63, Issue 2, Pages (February 2003)

Volume 80, Issue 10, Pages (November 2011)

Volume 58, Issue 3, Pages (September 2000)

Volume 60, Issue 6, Pages (December 2001)

Volume 56, Issue 2, Pages (August 1999)

Is complement a target for therapy in renal disease?

Importance of blood pressure control in hemodialysis patient survival

Recent developments in the management of secondary hyperparathyroidism

Volume 70, Issue 5, Pages (September 2006)

Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease Aquiles Jara, Arnold J. Felsenfeld, Jordi.

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Increased fetuin-A levels following treatment with a vitamin D analog

Volume 74, Issue 10, Pages (November 2008)

Volume 57, Issue 2, Pages (October 2000)

Stephen Pastan, J. Michael Soucie, William M. McClellan

Volume 82, Issue 1, Pages (July 2012)

Presentation transcript:

Volume 68, Issue 4, Pages 1840-1848 (October 2005) 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy Giorgio Coen, Daniela Mantella, Micaela Manni, Alessandro Balducci, Italo Nofroni, Daniela Sardella, Paola Ballanti, Ermanno Bonucci Kidney International Volume 68, Issue 4, Pages 1840-1848 (October 2005) DOI: 10.1111/j.1523-1755.2005.00603.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Monthly distribution of blood sampling for 25-hydroxyvitamin D (25-OHD) assay. The lines set the limits of 25-OHD groups. Kidney International 2005 68, 1840-1848DOI: (10.1111/j.1523-1755.2005.00603.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Serum calcitriol versus 25-hydroxyvitamin D (25-OHD) in 53 patients. Kidney International 2005 68, 1840-1848DOI: (10.1111/j.1523-1755.2005.00603.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Bone formation rate/bone surface (BFR/BS) versus 25-hydroxyvitamin D (25-OHD) serum levels in groups 1 + 2 and group 3. Regression lines are also reported. Kidney International 2005 68, 1840-1848DOI: (10.1111/j.1523-1755.2005.00603.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Bone formation rate/bone surface (BFR/BS) in the patients with increasing 25-hydroxyvitamin D (25-OHD) levels. Number of patients in each group are recorded. Kidney International 2005 68, 1840-1848DOI: (10.1111/j.1523-1755.2005.00603.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Osteoid thickness versus intact parathyroid hormone (iPTH) serum levels in the patients with serum 25-OHD values 0-20 (A) and >30 ng/mL (B). Kidney International 2005 68, 1840-1848DOI: (10.1111/j.1523-1755.2005.00603.x) Copyright © 2005 International Society of Nephrology Terms and Conditions